Zai-Pei Guo

Zai-Pei Guo

Auto-generated profile, based on publicly available information

Zai-Pei Guo

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2010 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
TCTao Chen
Tao Chen
ZGZai-Pei Guo
Zai-Pei Guo
XJXiao-Yan Jiao
Xiao-Yan Jiao
RJRui-Zhen Jia
Rui-Zhen Jia
YZYu-Hong Zhang
Yu-Hong Zhang
HLHong-Jie Liu
Hong-Jie Liu

26 February 2013 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
TCTao Chen
Tao Chen
ZGZai-Pei Guo
Zai-Pei Guo
LLLi Li
Li Li
LWLing Wang
Ling Wang
RJRui-Zhen Jia
Rui-Zhen Jia
MLMeng-Meng Li
Meng-Meng Li

4 August 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LZLiming Zhang
Liming Zhang
LQLi Qiu
Li Qiu
JWJian Wu
Jian Wu
YQYumeng Qi
Yumeng Qi
XGXinghua Gao
Xinghua Gao
TXTing Xiao
Ting Xiao

15 July 2011 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
TCT. Chen
T. Chen
ZGZ-P. Guo
Z-P. Guo
MLM-M. Li
M-M. Li
JLJ-Y. Li
J-Y. Li
XJX-Y. Jiao
X-Y. Jiao
HLH-J. Liu
H-J. Liu
Summary: Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumour necrosis factor (TNF) family, has been implicated as a proinflammatory cytokine in many types of autoimmune and infectious diseases. However, information about TWEAK in dermatological diseases is limited. Herein, we investigated the role of TWEAK in patients with Henoch–Schonlein purpura (HSP) and the ability of TWEAK on chemokine production in the human dermal microvascular endothelial cell line (HMEC-1). Serum TWEAK levels in patients with HSP, together with patients with psoriasis vulgaris (PV) and atopic dermatitis (AD), were detected by enzyme-linked immunosorbent assay (ELISA). HMEC-1 cells were treated with TWEAK at concentrations ranging from 1 ng/ml to 100 ng/ml. Serum levels of TWEAK were elevated in patients with HSP in the acute stage but not in patients with PV or AD. Moreover, TWEAK levels were correlated with the severity of HSP. TWEAK markedly induced CCL5 and CXCL8 production at both mRNA and protein levels in HMEC-1 cells. In addition, TWEAK-stimulated HMEC-1 supernatant enhanced HL-60 or human acute monocytic leukaemia cell line (THP-1) cell migration. Finally, Western blot data revealed that TWEAK can induce rapid phosphorylation of inhibitor of κB-α (IκBα) in HMEC-1 cells. In conclusion, we show that serum levels of TWEAK were elevated in patients with acute stage HSP. TWEAK may act as a regulator of nuclear factor-κB (NF-κB) activation and chemokine production in human dermal microvascular endothelial cells, thus promoting leucocyte migration in cutaneous vasculitis.

23 May 2013 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
TCTao Chen
Tao Chen
ZGZai‐Pei Guo
Zai‐Pei Guo
LWLin Wang
Lin Wang
SQSha Qin
Sha Qin
NCNa Cao
Na Cao
TWTing‐Ting Wang
Ting‐Ting Wang

14 November 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
XFXiaobin Fang
Xiaobin Fang
RLRen Liao
Ren Liao
YYYingyan Yu
Yingyan Yu
JLJingyi Li
Jingyi Li
ZGZaipei Guo
Zaipei Guo
TZTao Zhu
Tao Zhu
Background. Thrombin could elicit degranulation of mast cells involved in numerous physiologic and pathologic processes; however, the detailed scrutiny of this procedure and further research of possible cell signaling pathways are lacking.Methods. P815 mouse mast cells were exposed to various concentrations of thrombin for 16 h. Expression of protease-activated receptor (PAR)1, PAR2, PAR3, and PAR4 mRNA in P815 was analyzed by quantitative real-time PCR (qRT-PCR) and the fittest concentration of thrombin was decided. Then, secretions of mediators from P815 stimulated by thrombin 0.2 U/ml were determined using enzyme-linked immunosorbent assay (ELISA) and Luminex liquichip; the possible cell signaling pathways were measured by immunoblotting. Furthermore, inhibition of thrombin inhibitor (hirudin), PAR1 inhibitor (SCH79797), and MAPK inhibitors (SB203580, PD98059, and SP600125) on the mediator section was evaluated by ELISA and Luminex liquichip.Results. Thrombin 0.2 U/ml induced the elevated expression of PAR1, PAR2, PAR3, and PAR4, as well as the increasing level of phospho-IκBα, phospho-SAPK/JNK MAPK, phospho-P38 MAPK (Thr180/Tyr182), and phospho-ERK1/2 MAPK (p44/42) in P815. Secretion of vascular endothelial growth factor (VEGF), tumor necrosis factor-α(TNF-α), interleukin- (IL-) 2, IL-6, chemokine ligand- (CCL-) 2, chemokine (C-X-C motif) ligand- (CXCL-) 1, and CXCL-5 from P815 increased apparently; this effect could be diminished by hirudin, whereas SCH79797 and MAPK inhibitors (SB203580, PD98059, and SP600125) diminish the secretions with weaker effect.Conclusion. We found the expression of PAR mRNA in P815, activation of signaling pathways of nuclear factor-kappaB (NF-κB), and mitogen-activated protein kinases (MAPKs) including C-Jun NH2-terminal kinase (JNK), P38, and extracellular signal-regulated kinase 1/2 (ERK1/2), and the release of multiple inflammatory mediators stimulated by thrombin, as well as the inhibition of the inflammatory releases by hirudin, SCH79797, and MAPK inhibitors including SB203580, PD98059, and SP600125.